Cysteinyl leukotrienes in asthma: old mediators up to new tricks

Douglas W P Hay, Theodore J. Torphy, Bradley J Undem

Research output: Contribution to journalArticle

Abstract

The cysteinyl leukotrienes have long been suspected to play a role in the pathogenesis of asthma. This speculation was based largely on their release in human lung following antigen challenge as well as their potent bronchoconstrictor activity. However, there is increasing evidence that the cysteinyl leukotrienes also produce several pro-inflammatory effects and alter the activity of neuronal pathways in the airways. Douglas Hay, Theodore Torphy and Bradley Undem review these recent data and discuss the therapeutic possibilities of cysteinyl leukotriene receptor antagonists and 5-lipoxygenase inhibitors.

Original languageEnglish (US)
Pages (from-to)304-309
Number of pages6
JournalTrends in Pharmacological Sciences
Volume16
Issue number9
DOIs
StatePublished - 1995

Fingerprint

Asthma
Bronchoconstrictor Agents
Leukotriene Antagonists
Lipoxygenase Inhibitors
Antigens
Lung
cysteinyl-leukotriene
Therapeutics
leukotriene D4 receptor

ASJC Scopus subject areas

  • Pharmacology
  • Toxicology

Cite this

Cysteinyl leukotrienes in asthma : old mediators up to new tricks. / Hay, Douglas W P; Torphy, Theodore J.; Undem, Bradley J.

In: Trends in Pharmacological Sciences, Vol. 16, No. 9, 1995, p. 304-309.

Research output: Contribution to journalArticle

Hay, Douglas W P ; Torphy, Theodore J. ; Undem, Bradley J. / Cysteinyl leukotrienes in asthma : old mediators up to new tricks. In: Trends in Pharmacological Sciences. 1995 ; Vol. 16, No. 9. pp. 304-309.
@article{dfea2081ef0c4d00aeca9b1770be8ba6,
title = "Cysteinyl leukotrienes in asthma: old mediators up to new tricks",
abstract = "The cysteinyl leukotrienes have long been suspected to play a role in the pathogenesis of asthma. This speculation was based largely on their release in human lung following antigen challenge as well as their potent bronchoconstrictor activity. However, there is increasing evidence that the cysteinyl leukotrienes also produce several pro-inflammatory effects and alter the activity of neuronal pathways in the airways. Douglas Hay, Theodore Torphy and Bradley Undem review these recent data and discuss the therapeutic possibilities of cysteinyl leukotriene receptor antagonists and 5-lipoxygenase inhibitors.",
author = "Hay, {Douglas W P} and Torphy, {Theodore J.} and Undem, {Bradley J}",
year = "1995",
doi = "10.1016/S0165-6147(00)89059-8",
language = "English (US)",
volume = "16",
pages = "304--309",
journal = "Trends in Pharmacological Sciences",
issn = "0165-6147",
publisher = "Elsevier Limited",
number = "9",

}

TY - JOUR

T1 - Cysteinyl leukotrienes in asthma

T2 - old mediators up to new tricks

AU - Hay, Douglas W P

AU - Torphy, Theodore J.

AU - Undem, Bradley J

PY - 1995

Y1 - 1995

N2 - The cysteinyl leukotrienes have long been suspected to play a role in the pathogenesis of asthma. This speculation was based largely on their release in human lung following antigen challenge as well as their potent bronchoconstrictor activity. However, there is increasing evidence that the cysteinyl leukotrienes also produce several pro-inflammatory effects and alter the activity of neuronal pathways in the airways. Douglas Hay, Theodore Torphy and Bradley Undem review these recent data and discuss the therapeutic possibilities of cysteinyl leukotriene receptor antagonists and 5-lipoxygenase inhibitors.

AB - The cysteinyl leukotrienes have long been suspected to play a role in the pathogenesis of asthma. This speculation was based largely on their release in human lung following antigen challenge as well as their potent bronchoconstrictor activity. However, there is increasing evidence that the cysteinyl leukotrienes also produce several pro-inflammatory effects and alter the activity of neuronal pathways in the airways. Douglas Hay, Theodore Torphy and Bradley Undem review these recent data and discuss the therapeutic possibilities of cysteinyl leukotriene receptor antagonists and 5-lipoxygenase inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=0029152856&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029152856&partnerID=8YFLogxK

U2 - 10.1016/S0165-6147(00)89059-8

DO - 10.1016/S0165-6147(00)89059-8

M3 - Article

C2 - 7482995

AN - SCOPUS:0029152856

VL - 16

SP - 304

EP - 309

JO - Trends in Pharmacological Sciences

JF - Trends in Pharmacological Sciences

SN - 0165-6147

IS - 9

ER -